FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386168759> ?p ?o ?g. }

• W4386168759 endingPage "2223" @default.
• W4386168759 startingPage "2216" @default.
• W4386168759 abstract "Elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) are risk factors for atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an RNA interference therapy that targets angiopoietin-like protein 3 (ANGPTL3), a regulator of lipoprotein metabolism. This first-in-human, phase 1, randomized, placebo-controlled, open-label trial investigated single and repeat ARO-ANG3 doses in four cohorts of fifty-two healthy participants and one cohort of nine participants with hepatic steatosis, part of a basket trial. Safety (primary objective) and pharmacokinetics (in healthy participants) and pharmacodynamics (secondary objectives) of ARO-ANG3 were evaluated. ARO-ANG3 was generally well tolerated, with similar frequencies of treatment-emergent adverse events in active and placebo groups. Systemic absorption of ARO-ANG3 in healthy participants was rapid and sustained, with a mean Tmax of 6.0-10.5 h and clearance from plasma within 24-48 h after dosing with a mean t½ of 3.9-6.6 h. In healthy participants, ARO-ANG3 treatment reduced ANGPTL3 (mean -45% to -78%) 85 days after dose. Reductions in triglyceride (median -34% to -54%) and non-HDL-C (mean -18% to -29%) (exploratory endpoints) concentrations occurred with the three highest doses. These early-phase data support ANGPTL3 as a potential therapeutic target for ASCVD treatment. ClinicalTrials.gov identifier: NCT03747224." @default.
• W4386168759 created "2023-08-26" @default.
• W4386168759 creator A5001058333 @default.
• W4386168759 creator A5001549960 @default.
• W4386168759 creator A5002935320 @default.
• W4386168759 creator A5003834872 @default.
• W4386168759 creator A5012038189 @default.
• W4386168759 creator A5020003074 @default.
• W4386168759 creator A5026199172 @default.
• W4386168759 creator A5028045704 @default.
• W4386168759 creator A5052604218 @default.
• W4386168759 creator A5058758956 @default.
• W4386168759 creator A5066507748 @default.
• W4386168759 creator A5072796310 @default.
• W4386168759 creator A5079564889 @default.
• W4386168759 creator A5082366563 @default.
• W4386168759 creator A5083791996 @default.
• W4386168759 creator A5089509231 @default.
• W4386168759 creator A5090781778 @default.
• W4386168759 creator A5091197396 @default.
• W4386168759 date "2023-08-25" @default.
• W4386168759 modified "2023-10-18" @default.
• W4386168759 title "RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts" @default.
• W4386168759 cites W1944135887 @default.
• W4386168759 cites W1958022600 @default.
• W4386168759 cites W2103334195 @default.
• W4386168759 cites W2106937178 @default.
• W4386168759 cites W2156718297 @default.
• W4386168759 cites W2462595066 @default.
• W4386168759 cites W2604768034 @default.
• W4386168759 cites W2617605538 @default.
• W4386168759 cites W2618984243 @default.
• W4386168759 cites W2757794608 @default.
• W4386168759 cites W2761312904 @default.
• W4386168759 cites W2767569336 @default.
• W4386168759 cites W2925074214 @default.
• W4386168759 cites W2949132703 @default.
• W4386168759 cites W2955013370 @default.
• W4386168759 cites W2969391566 @default.
• W4386168759 cites W2991262768 @default.
• W4386168759 cites W2999177103 @default.
• W4386168759 cites W3041635484 @default.
• W4386168759 cites W3044543495 @default.
• W4386168759 cites W3061843793 @default.
• W4386168759 cites W3082366829 @default.
• W4386168759 cites W3206727734 @default.
• W4386168759 cites W4229019883 @default.
• W4386168759 cites W4280490948 @default.
• W4386168759 cites W4308367139 @default.
• W4386168759 doi "https://doi.org/10.1038/s41591-023-02494-2" @default.
• W4386168759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37626170" @default.
• W4386168759 hasPublicationYear "2023" @default.
• W4386168759 type Work @default.
• W4386168759 citedByCount "2" @default.
• W4386168759 crossrefType "journal-article" @default.
• W4386168759 hasAuthorship W4386168759A5001058333 @default.
• W4386168759 hasAuthorship W4386168759A5001549960 @default.
• W4386168759 hasAuthorship W4386168759A5002935320 @default.
• W4386168759 hasAuthorship W4386168759A5003834872 @default.
• W4386168759 hasAuthorship W4386168759A5012038189 @default.
• W4386168759 hasAuthorship W4386168759A5020003074 @default.
• W4386168759 hasAuthorship W4386168759A5026199172 @default.
• W4386168759 hasAuthorship W4386168759A5028045704 @default.
• W4386168759 hasAuthorship W4386168759A5052604218 @default.
• W4386168759 hasAuthorship W4386168759A5058758956 @default.
• W4386168759 hasAuthorship W4386168759A5066507748 @default.
• W4386168759 hasAuthorship W4386168759A5072796310 @default.
• W4386168759 hasAuthorship W4386168759A5079564889 @default.
• W4386168759 hasAuthorship W4386168759A5082366563 @default.
• W4386168759 hasAuthorship W4386168759A5083791996 @default.
• W4386168759 hasAuthorship W4386168759A5089509231 @default.
• W4386168759 hasAuthorship W4386168759A5090781778 @default.
• W4386168759 hasAuthorship W4386168759A5091197396 @default.
• W4386168759 hasBestOaLocation W43861687591 @default.
• W4386168759 hasConcept C111113717 @default.
• W4386168759 hasConcept C112705442 @default.
• W4386168759 hasConcept C126322002 @default.
• W4386168759 hasConcept C134018914 @default.
• W4386168759 hasConcept C142724271 @default.
• W4386168759 hasConcept C197934379 @default.
• W4386168759 hasConcept C204787440 @default.
• W4386168759 hasConcept C27081682 @default.
• W4386168759 hasConcept C2777288759 @default.
• W4386168759 hasConcept C2778163477 @default.
• W4386168759 hasConcept C2778913445 @default.
• W4386168759 hasConcept C2780072125 @default.
• W4386168759 hasConcept C2780948078 @default.
• W4386168759 hasConcept C43554185 @default.
• W4386168759 hasConcept C71924100 @default.
• W4386168759 hasConcept C72563966 @default.
• W4386168759 hasConcept C98274493 @default.
• W4386168759 hasConceptScore W4386168759C111113717 @default.
• W4386168759 hasConceptScore W4386168759C112705442 @default.
• W4386168759 hasConceptScore W4386168759C126322002 @default.
• W4386168759 hasConceptScore W4386168759C134018914 @default.
• W4386168759 hasConceptScore W4386168759C142724271 @default.
• W4386168759 hasConceptScore W4386168759C197934379 @default.
• W4386168759 hasConceptScore W4386168759C204787440 @default.

• next